References
- Merlini G, Bellotti V. Molecular mechanisms of amyloidosis.
N Engl J Med. 2003; 349(6): 583-596. PubMed | Google
Scholar
- Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker
L, Hermine O et al. High-dose melphalan versus melphalan plus dexamethasone
for AL amyloidosis. N Engl J Med. 2007; 357(11): 1083-93. PubMed | Google
Scholar
- Merlini G, Stone MJ. Dangerous small B-cell clones.
Blood. 2006; 108(8): 2520-2530. PubMed | Google
Scholar
- Jaccard A, Desport E, Mohty D, Bridoux F. Amylose
AL. Rev Med Int. 2015; 36(2): 89-97. PubMed | Google
Scholar
- Dispenzieri A, Gertz MA, Buadi F. What do I need
to know about immunoglobulin light chain (AL) amyloidosis? Blood Rev.
2012; 26(4): 137-4. Google
Scholar
- Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis,
Tours, France, 18-22 April 2004. Am J Hematol. 2005; 79(4): 319-328. PubMed | Google
Scholar
- Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt
MF, Therneau TM et al. Serum cardiac troponins and N-terminal pro-brain
natriuretic peptide: a staging system for primary systemic amyloidosis.
J Clin Oncol. 2004; 22(18): 3751-. PubMed | Google
Scholar
- Palladini G, Dispenzieri A, Gertz MA, Kumar S, Wechalekar
A, Hawkins PN et al. New criteria for response to treatment
in immunoglobulin light chain amyloidosis based on free light chain measurement
and cardiac
biomarkers: impact on survival outcomes. J Clin Oncol.
2012; 30(36): 4541-9. PubMed | Google
Scholar
- Palladini G, Hegenbart U, Milani P, Kimmich C, Foli
A, Ho AD et al. A staging system for renal outcome
and early markers of renal response to chemotherapy in AL amyloidosis.
Blood. 2014; 124(15): 2325-32. PubMed | Google
Scholar
- Jaccard A, Desport E, Mohty D, Bridoux F. AL amyloidosis.
Rev Med Int. 2015; 36(2): 89-97. PubMed | Google
Scholar
- Brambilla F, Lavatelli F, Di Silvestre D et al.
Reliable typing of systemic amyloidoses through proteomic
analysis of subcutaneous adipose tissue. Blood. 2012; 119(8): 1844-1847. PubMed | Google
Scholar
- Comenzo RL, Reece D, Palladini G, Seldin D, Sanchorawala
V, Landau H et al. Consensus guidelines for the conduct
and reporting of clinical trials in systemic light-chain amyloidosis.
Leukemia. 2012;
26(11): 2317-2325. PubMed | Google
Scholar
- Palladini G, Foli A, Milani P, Russo P, Albertini
R, Lavatelli F et al. Best use of cardiac biomarkers
in patients with AL amyloidosis and renal failure. Am J Hematol. 2012;
87(5): 465-471. PubMed | Google
Scholar
- Chaulagain CP, Comenzo RL. How we treat systemic
light-chain amyloidosis. Clin Adv Hematol Oncol. 2015;
13(5): 315-24. PubMed | Google
Scholar
- Palladini G, Russo P, Nuvolone M, Lavatelli F,
Perfetti V, Obici L et al. Treatment with oral melphalan
plus dexamethasone produces long-term remissions in AL amyloidosis. Blood.
2007; 110(2): 787-788. PubMed | Google
Scholar
- Palladini G, Milani P, Foli A, Obici L, Lavatelli
F, Nuvolone M et al. Oral melphalan and dexamethasone grants extended
survival with minimal toxicity in AL amyloidosis: longterm results of
a risk-adapted approach. Haematologica. 2014; 99(4): 743-50. PubMed | Google
Scholar
- Kastritis E, Dimopoulos MA. Recent advances in
the management of AL Amyloidosis. Br J Haematol. 2016;
172(2): 170-86. PubMed | Google
Scholar
- Merlini G, Palladini G. Treating advanced cardiac
damage in light chain amyloidosis: still an unmet need.
Haematologica. 2014; 99(9): 1407-1409. PubMed | Google
Scholar
- Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello
N, Spong J, Reeder CB et al. Cyclophosphamide-bortezomib-dexamethasone
(CyBorD) produces rapid and complete hematologic response in patients
with AL amyloidosis. Blood. 2012; 119(19): 4391-4. PubMed | Google
Scholar